Hernández-Rivas, JA, Prat, AM, Ponce, ES, Medina, A, Lluch-García, R, Oliveira, ACD, Rodriguez-Fernandez, A, Soler, JA, Terol-Castera, MJ, Machado-Machado, P, Pérez-Encinas, M, Romero-Carmona, R, Segundo, LYS, García-Martin, P, Mompo, C, Zubillaga-Marban, E. First worldwide real-life data on fixed-duration ibrutinib plus venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain's LI plus VE observational study. BLOOD. 2025; 146DOI:10.1182/blood-2025-2728. PMID:. IF:23.100(Q1/1D).

Niebla, AM, Gine, E, Bastos-Oreiro, M, Perez, A, Cabirta, A, Vicente, FD, Vilaseca, MC, Ubieto, AJ, De Villambrosia, SG, Prat, AM, Barca, EG, Henriquez, HDL, Herranz, ER, Prieto, PG, Cordoba, R, Carreres, AS, Garcia-Sancho, AM, Moya, AMGN, Grande, C, Martine, PP, Nicolas, C, Gutierrez, A, Rivas, JAH, Sanchez-Gonzalez, B, Villalobos, MT, Garcia-Cerecedo, T, Trillo, RA, Donato, E, Gutierrez, PV, Belmonte, DG, Cozzarelli, SRV, Ordoñez, SS, De La Mano, EP, Avaría, A, Blanco, LV, Roldan-Perez, A, Sancho, JM, De la Cruz, B, Prince-Eladnani, R, Abrisqueta, P. Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study. BLOOD. 2025; 146DOI:10.1182/blood-2025-3592. PMID:. IF:23.100(Q1/1D).

Chatzikonstantinou, T, Agathangelidis, A, Talimtzi, P, Laidou, S, Minga, E, Roussos, A, Angelopoulou, M, De Tomas, MA, Antic, D, Baran-Marszak, F, Bödör, C, Albareda, FB, Catherwood, M, Chatzileontiadou, S, Chessa, C, Coscia, M, Crespo, M, Cuneo, A, Davis, Z, Dimou, M, Doubek, M, Efstathopoulou, M, Espinet, B, Gaidano, G, Gupta, R, Hatzimichael, E, Herishanu, Y, Karamanli, T, Konstantinou, E, Kotsianidis, I, Koumpis, AE, Laszlo, T, Levy, V, Machairas, A, Martini, F, Moia, R, Mouhssine, S, Prat, AM, Murru, R, Mpalaoura, E, Pangalis, G, Papaioannou, M, Pavlova, S, Plevova, K, Pospisilova, S, Puiggros, A, Rani, L, Rigolin, GM, Romano, I, Rossi, D, Serna, A, Simkovic, M, Smolej, L, Stavrogianni, N, Vujovic, KT, Trentin, L, Vassilakopoulos, T, Visentin, A, Vitale, C, Vrachiolias, G, Scarfo, L, Chatzidimitriou, A, Ghia, P, Stamatopoulos, K. Dissecting the heterogeneity of IGHV-mutated CLL: An eric study. BLOOD. 2025; 146DOI:10.1182/blood-2025-2120. PMID:. IF:23.100(Q1/1D).

Bastos-Oreiro, M, Cabirta, A, Perez, A, Carreres, AS, De Villambrosia, SG, Canelo, M, Moya, AMGN, Benito, BD, Gutiérrez, PV, Vicente, FD, Caballero, JC, Jiménez-Ubieto, A, Belmonte, DG, Prat, AM, Barca, EG, Henríquez, HDL, Herranz, ER, Garcia-Sancho, AM, Grande, C, Nicolás, C, Gutierrez, A, Gomez-Llobell, M, Rivas, JAH, Sánchez-González, B, Campos, AF, Trillo, RA, Donato, E, Cozzarell, SRV, Ordoñez, SS, De La Mano, EP, Prieto, PG, Avaria, A, Blanco, LV, Roldán-Pérez, A, Cordoba, R, Sancho, JM, Gine, E, Garces, VN, Abrisqueta, P, Niebla, AM. Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group. BLOOD. 2025; 146DOI:10.1182/blood-2025-3585. PMID:. IF:23.100(Q1/1D).

Gabarros-Subira, M, Torres-Esquius, S, Pomares, H, Beas, F, Suárez-Gonzalez, J, Sanchez, AH, Lopez-Fernandez, E, López, GR, Hermosin-Ramos, M, Carreño, G, Castillo, IM, García, JD, Santiago, M, Pascual, M, Díaz-Beyá, M, Carrascosa, GB, Montoya, RT, Ortuño, FJ, Vives, S, Mañó, LG, Casares, MTG, Alfonso-Pierola, A, Pris-Vilaespesa, M, Revilla, N, Alonso, S, Iborra, A, Lores, BF, Díaz, RMA, Cervera, J, Corral, LL, Canela, MP, Buño, I, Montoro, MJ, Hernandez, F, Albareda, FB, Arnan, M, Valcarcel, D, Martinez-Laperche, C, Jerez, A. Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers. BLOOD. 2025; 146DOI:10.1182/blood-2025-4275. PMID:. IF:23.100(Q1/1D).

Riedell, PA, Kwon, M, Flinn, IW, Dickinson, MJ, Solano, C, Jaeger, U, Briones, J, Kato, K, Fleming, S, Bachy, E, Rambaldi, A, Shune, LO, Shah, NN, Blaise, D, Frigault, MJ, Ramakrishnan, A, Yang, A, Pearson, D, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).